• Knight Therapeutics reported Q2 2026 revenue of CAD 144.21 million, up 34% from a year earlier.
• Operating income was CAD 8.96 million, swinging from an operating loss a year earlier.
• Net loss narrowed to CAD 3.36 million; net loss per share improved to CAD 0.03.
• Adjusted EBITDA (non-IFRS) rose 58% to CAD 24.57 million; cash inflow from operations was CAD 29.52 million.
• Raised 2026 revenue outlook to CAD 540 million–CAD 560 million; adjusted EBITDA expected at least 15% of revenue.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Knight Therapeutics Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.